drugset / Trial / NCT01546558

Single Cohort, 2-Period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine 500 mg

NCT01546558

Phase 1 Completed 25 enrolled Gilead Sciences
NaSingle-groupOpen-label

Summary

The purpose of this study is to evaluate the effect of steady-state ranolazine 500 mg bid on the steady state pharmacokinetics (PK) of metformin in subjects with type 2 diabetes mellitus (T2DM).

Timeline

Start
2012-02
Primary completion
2012-03
Completion
2012-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Metformin Small molecule 1000 mg
Subject Ranolazine Small molecule 500 mg